Clinical Trials
74 trialsNCT03520686 2026-05-26
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT02106572 2026-05-22
TIM
Abnoba Gmbh
Phase 3 Terminated
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT02200042 2026-05-19
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
NRG Oncology
Phase 3 Terminated
NCT04158141 2026-05-19
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Phase 3 Terminated
NCT04154956 2026-05-18
CARMEN-LC03
Sanofi
Phase 3 Terminated
NCT03426371 2026-05-12
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Terminated
NCT04746924 2026-05-12
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
BeOne Medicines
Phase 3 Terminated
NCT04251533 2026-05-11
EPIK-B3
Novartis
Phase 3 Terminated
NCT04261777 2026-04-28
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
Saving Patients' Lives Medical B.V.
Phase 3 Terminated
NCT06125028 2026-04-28
LYMFOR
Pentixapharm AG
Phase 3 Terminated
NCT02525211 2026-04-21
Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment
Institut Paoli-Calmettes
Phase 3 Terminated
NCT05171075 2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT01507506 2026-04-14
SPECTRO GLIO
Institut Claudius Regaud
Phase 3 Terminated
NCT01366612 2026-04-03
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT05009290 2026-04-03
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT05937672 2026-04-03
Cold Atmospheric Plasma Device Extension Study
Medical University of South Carolina
Phase 3 Terminated
NCT03085004 2026-03-30
CHARM
Milton S. Hershey Medical Center
Phase 3 Terminated
NCT04689594 2026-03-27
A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group
CellSeed Inc.
Phase 3 Terminated
NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
NCT01613482 2026-03-16
TSARINE
Centre Oscar Lambret
Phase 3 Terminated
NCT02173756 2026-03-16
MorphinOgel
University Hospital, Strasbourg, France
Phase 3 Terminated
NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
NCT06038539 2026-03-13
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Biocon Limited
Phase 3 Terminated
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT06587451 2026-02-24
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz
Phase 3 Terminated
NCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT04876651 2026-02-20
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Terminated
NCT05386550 2026-02-19
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
EMD Serono
Phase 3 Terminated
NCT05223647 2026-01-28
TRIPLEX
Norwegian University of Science and Technology
Phase 3 Terminated
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT04266301 2026-01-13
STIMULUS-MDS2
Novartis
Phase 3 Terminated
NCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT03042169 2025-12-23
SURGIGAST
University Hospital, Lille
Phase 3 Terminated
NCT03924869 2025-12-11
KEYNOTE-867
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT06280196 2025-12-02
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Bio-Thera Solutions
Phase 3 Terminated
NCT04485104 2025-10-31
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Jazz Pharmaceuticals
Phase 3 Terminated
NCT01546571 2025-10-24
MAVIS
Polynoma LLC
Phase 3 Terminated
NCT04551066 2025-10-21
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation
Phase 3 Terminated
NCT00210236 2025-10-20
AXIL95
Institut Bergonié
Phase 3 Terminated
NCT04459715 2025-10-08
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
EMD Serono
Phase 3 Terminated
NCT03216187 2025-10-07
PREVENT
University Hospital, Geneva
Phase 3 Terminated
NCT03598712 2025-10-06
CLODIS
Centre Francois Baclesse
Phase 3 Terminated
NCT04161885 2025-10-06
VIALE-T
AbbVie
Phase 3 Terminated
NCT04458909 2025-10-03
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT04551053 2025-10-02
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
Phase 3 Terminated
NCT05604170 2025-10-01
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Marinus Pharmaceuticals
Phase 3 Terminated